Panzyga (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Panzyga, is an immunoglobulin presented as a 10% solution for intravenous use. It treats primary immunodeficiency diseases and provides immune support in patients with antibody deficiencies. GNH USA supplies Panzyga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

GNH USA supplies Panzyga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Panzyga is an immunoglobulin used to replace missing antibodies in primary immunodeficiency disorders and related immune‑deficiency conditions.

- Primary immunodeficiency disease (PID): restores normal levels of IgG and reduces infection frequency. - Secondary immunodeficiency (e.g., chronic lymphocytic leukemia): provides passive immunity to help prevent bacterial infections. - Post‑transplant immune support: supplies antibodies to patients whose own immune system is suppressed after organ transplantation. - Antibody deficiency secondary to chemotherapy: supports immune function during cancer treatment. - Primary antibody deficiency (CVID): maintains protective IgG concentrations and reduces need for antibiotics.

Adverse reactions to Panzyga are generally related to the infusion process and the immunoglobulin content.

Common Side Effects: - Headache - Fatigue - Mild fever - Chills - Nausea - Injection site erythema

Serious or Rare Side Effects: - Anaphylactic reaction - Acute renal failure - Thromboembolic events - Aseptic meningitis - Hemolytic anemia - Severe hypotension

When using Panzyga, clinicians should assess patient history and monitor for specific safety concerns.

- Renal function: evaluate baseline kidney function and adjust infusion rate in renal impairment. - Thrombotic risk: assess history of clotting disorders before initiating therapy. - Cardiovascular status: monitor blood pressure during infusion, especially in patients with cardiac disease. - Allergic history: verify no prior severe reactions to immunoglobulin products. - Concomitant immunosuppressants: watch for increased infection risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Panzyga may interact with other medicines that affect immune function or renal clearance.

Major Interactions (Avoid): - Live vaccines: concurrent use may reduce vaccine efficacy and increase adverse events. - Nephrotoxic drugs (e.g., aminoglycosides): combined use can worsen renal impairment.

Moderate Interactions (Monitor Closely): - Anticoagulants: immunoglobulin can alter coagulation parameters, requiring INR monitoring.\n- Corticosteroids: may increase risk of fluid overload and hypertension. - Diuretics: monitor electrolytes and volume status during infusion. - ACE inhibitors: watch for additive effects on blood pressure. - Rituximab: combined therapy may affect B‑cell recovery dynamics.